TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

MLTX INVESTOR REMINDER: MoonLake Immunotherapeutics Investors may have been Affected by Fraud -- Contact BFA Law if You Suffered Losses

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Bleichmar Fonti & Auld Llp
MLTX INVESTOR REMINDER: MoonLake Immunotherapeutics Investors may have been Affected by Fraud -- Contact BFA Law if You Suffered Losses

MoonLake Immunotherapeutics faces a securities fraud lawsuit after reporting disappointing Phase 3 trial results for its investigational drug sonelokimab, causing its stock price to drop nearly 90%.

Insights
GOOGL   neutral

Anticipated 6% revenue and 7% earnings growth, market sensitivity to AI investment narrative


MLTX   negative

Stock price collapsed by 90% after failed Phase 3 trials, with allegations of misleading investors about clinical data and drug effectiveness